Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT001 in MSA
NCT07476352Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ALT001 in multiple system atrophy (MSA). Primary endpoints: Adverse Events and Serious Adverse Events at 180 days and Unified Multiple System Atrophy Rating Scale at 180 days. Started Jun 2026; status: recruiting.
02
Drugs
ALT001
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT07476352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476352.